First Tracks Biotherapeutics Announces $200 Million Private Placement

First Tracks Biotherapeutics announced a $200 million private placement of 6,106,870 shares at $32.75 per share to a group of institutional investors. Proceeds are earmarked for general corporate purposes, including clinical development of ANB033, a CD122 antagonist in development for celiac disease and eosinophilic esophagitis. Leerink Partners, Piper Sandler, UBS Investment Bank and Wells Fargo Securities are acting as placement agents; the deal is expected to close October 19, 2026, with a resale registration statement to be filed.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.